HIV &
Incarceration

By the numbers

The intersection of HIV and mass incarceration is one of the most underreported — and consequential — drivers of the ongoing U.S. HIV epidemic. It is a crisis that happens largely out of public view, inside institutions that are difficult to study and politically inconvenient to reform. The Bureau of Justice Statistics counted 12,460 people living with HIV in U.S. state and federal prisons at year-end 2023 — an increase of about 2% from 2022 (12,200) and the second year in a row that the count has risen¹. Prevalence works out to roughly 1,144 per 100,000 among people in prison — about three times the 380 per 100,000 rate in the general population².

Why HIV rates are higher in correctional settings

The elevated HIV prevalence in correctional facilities is not primarily a product of what happens inside — it is a product of who is incarcerated. The U.S. criminal justice system disproportionately incarcerates the same communities that are disproportionately affected by HIV: Black and Latino men, people who inject drugs, people who have engaged in sex work, and people experiencing poverty and housing instability.

When you concentrate people from high-HIV-prevalence communities into a single setting, you concentrate HIV. This is not a moral statement about incarcerated people — it is a structural observation about who is caught in the criminal justice system and why.

The role of drug policy

The war on drugs has driven mass incarceration of people who inject drugs — the population that faces HIV transmission risk through needle sharing. Incarcerating rather than treating people with substance use disorders removes them from harm reduction services (syringe programs, naloxone, MAT) and concentrates HIV risk without addressing its roots.

The role of sex work criminalization

Criminalization of sex work drives repeated incarceration of people — disproportionately women and transgender women of color — who face elevated HIV risk. Each incarceration cycle disrupts HIV care, treatment, and prevention for some of the most vulnerable people in the epidemic.

HIV inside correctional facilities

Sexual transmission

Consensual and non-consensual sex occurs inside correctional facilities. The vast majority of U.S. prisons and jails do not distribute condoms: only two state prison systems (California and Vermont — Mississippi's is limited to conjugal visits) and five city or county jail systems (Los Angeles, New York City, San Francisco, Philadelphia, and Washington, D.C.) provide them³. This is despite CDC guidance for correctional facilities that people with HIV, viral hepatitis, or STIs should receive counseling on prevention and condom use as part of standard care⁴. The refusal to provide condoms is a policy choice that trades HIV prevention for a pretense that sex doesn't happen inside.

Injection drug use

Drug use continues inside correctional facilities. Injecting drugs with shared equipment — driven by the scarcity of clean needles inside — creates HIV transmission risk. Syringe programs do not exist in U.S. prisons. Some countries (Canada, some European nations) have implemented prison-based syringe programs with documented reductions in HIV transmission; the U.S. has not.

Tattooing

Tattooing is common in correctional settings and typically done with improvised equipment shared among multiple people. Shared tattooing equipment is a known — if underappreciated — HIV transmission risk inside facilities.

Sexual violence

Sexual violence in correctional settings is a real and documented problem. The Prison Rape Elimination Act (PREA) was passed in 2003 specifically to address this — but implementation has been inconsistent, and survivors often face barriers to accessing PEP after assault. HIV transmission through sexual violence in correctional settings is a public health and human rights issue that rarely receives adequate attention.

Testing at intake: what CDC recommends, what happens in practice

The CDC recommends that correctional and detention facilities offer HIV screening on an opt-out basis — meaning people are tested unless they specifically decline — because prevalence in these settings is high enough to warrant it⁴. Opt-out testing dramatically increases the number of people who learn their status compared to opt-in models.

In practice, though, only 29 of 50 U.S. jurisdictions — including the federal Bureau of Prisons — conducted opt-out HIV testing at custody intake as of 2023, according to BJS¹. The rest test only when a person requests a test, when there is a clinical indication, or not at all. That gap means thousands of people who could be diagnosed at intake — and started on ART inside — instead remain undiagnosed until release, when their care becomes far harder to sustain.

HIV care gaps inside

ART access at intake

For people already on HIV treatment, incarceration creates immediate risk. The intake process — booking, processing, medical screening — can take days to weeks, during which ART may be unavailable or interrupted. Even 10–14 days off ART can cause viral rebound in some people, undermining suppression and increasing transmission risk⁵. Medication continuity at intake is a critical gap that correctional healthcare advocates have identified for decades.

Quality of care inside

Constitutional law establishes that incarcerated people have a right to adequate medical care. In Estelle v. Gamble (1976), the Supreme Court held that "deliberate indifference to serious medical needs of prisoners" by prison staff violates the Eighth Amendment's ban on cruel and unusual punishment⁶. In practice, that standard sets a floor — "adequate," not optimal — and enforcement requires litigation. HIV care inside U.S. correctional facilities varies enormously, from some systems with competent HIV specialists and modern ART regimens to facilities where people living with HIV struggle to receive consistent medication, viral load monitoring, or specialist referrals.

PrEP is almost never available inside U.S. correctional facilities — even for HIV-negative incarcerated people at high risk. This is a gap that reflects both resource constraints and a political unwillingness to invest in HIV prevention inside prisons.

Mental health and HIV

Incarcerated people living with HIV face compounded mental health burdens: the psychological impact of incarceration, trauma (including from sexual violence), stigma about HIV status inside facilities (which can be severe and occasionally violent), and the stress of navigating both HIV care and legal situations at the same time. Mental health services inside are often inadequate for the general population, let alone the complex needs of people living with HIV.

The re-entry crisis

The period immediately after release from incarceration is one of the periods of highest HIV transmission risk in the U.S. epidemic — and for people living with HIV, one of the most dangerous windows for treatment interruption. Because Undetectable = Untransmittable (U=U) depends on staying virally suppressed⁷, even short gaps in ART at re-entry can undo years of hard-won suppression. Peer-reviewed research documents high rates of viral rebound in the weeks following release⁵. Multiple crises converge at once:

Insurance and medication gaps

Most incarcerated people lose any prior health coverage during incarceration. Upon release, they face a gap before new coverage begins. HIV medications are expensive and cannot be interrupted without risk. The re-enrollment process for Medicaid, Ryan White, or ADAP takes time — time during which viral load can rebound.

Housing instability

People released from incarceration face extremely high rates of homelessness — particularly in the first 30 days after release. Stable housing is one of the strongest predictors of HIV treatment success. Without it, keeping appointments, storing medication safely, and maintaining treatment routine become nearly impossible. The HIV–incarceration–homelessness nexus is one of the most intractable problems in HIV care.

Loss of medical continuity

Medical records may not transfer smoothly from correctional facilities to community providers. HIV specialists in the community may have no history for a newly released patient. Resistance testing results, prior regimen history, and other clinical information can be lost in the transition.

Medicaid reentry waivers: a fix Florida hasn't adopted

Since 2023, the Centers for Medicare & Medicaid Services (CMS) has allowed states to apply for Section 1115 "reentry" demonstration waivers. These waivers create a limited exception to the longstanding federal "inmate exclusion" rule, so Medicaid can pay for a defined set of pre-release services in the last 30–90 days before someone leaves prison or jail. Every approved waiver must include, at minimum: case management, medications for substance use disorder, and a 30-day supply of all prescription medications at the time of release — which, for people living with HIV, means walking out the gate with ART in hand⁸.

As of late 2025, 19 states had approved reentry waivers (Arizona, California, Colorado, Hawaii, Illinois, Kentucky, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Mexico, North Carolina, Oregon, Pennsylvania, Utah, Vermont, Washington, and West Virginia) with nine more pending⁹. The Center for Health Law and Policy Innovation is tracking which state waivers specifically expand HIV and hepatitis C prevention and treatment before release¹⁰.

What a good HIV discharge plan looks like

Programs that actively plan for release — instead of releasing people at midnight with a paper bag and a bus ticket — have measurably better HIV outcomes¹¹. HRSA's HIV/AIDS Bureau Policy Clarification Notice 18-02 authorizes Ryan White programs to provide transitional services to people leaving jails and prisons on a time-limited basis (generally up to 180 days), specifically so that gap is bridged¹². A working pre-release plan should include:

• A 30-day (or longer) supply of ART in hand at release — not a prescription to fill later.
• An appointment already booked with a community HIV provider or Ryan White clinic within 7–14 days of release.
• Insurance in place before the door opens — Medicaid re-activated (not just re-applied for), Ryan White eligibility confirmed, and ADAP enrollment started.
• A warm handoff: the inside clinician talks to the outside clinician, ideally by phone or in a shared record, before the transfer¹².
• A housing plan. If housing is not stable, connect the person to housing case management (HOPWA in Florida) before release — not after.
• Contact information for a peer navigator or reentry coach — someone who has been through it and can be reached that first week.
• A written medical summary the person can carry: current regimen, last viral load and CD4, resistance history, allergies, and any co-conditions (hep C, mental health, substance use).

Race, mass incarceration, and HIV

The HIV-incarceration intersection cannot be understood without confronting the racial dimensions of mass incarceration in the U.S. Black Americans are incarcerated at approximately five times the rate of white Americans. Latino Americans are incarcerated at roughly twice the rate of white Americans. These disparities are themselves driven by structural racism — in policing, prosecution, sentencing, and the political economy of the criminal justice system.

The result: mass incarceration amplifies and perpetuates HIV disparities in Black and Latino communities. Every time a person is cycled through the criminal justice system with interrupted HIV care, the damage extends beyond that individual — to their sexual partners, their family networks, their communities. The racial injustice of mass incarceration and the racial injustice of the HIV epidemic are not separate problems.

Addressing HIV in correctional settings is, among other things, a racial justice issue. Decarceration — reducing the number of people incarcerated, particularly for low-level drug offenses — would have direct public health benefits for HIV outcomes in Black and Latino communities.

Trans and gender-nonconforming people in custody

Transgender women — particularly Black and Latina trans women — are dramatically over-represented in the U.S. HIV epidemic and in the U.S. carceral system. Human Rights Watch, in a South Florida–focused report, documented that roughly one in five trans women in the U.S. has been incarcerated, and that the rate among Black trans women is about three times higher than among white trans women, with some studies finding a lifetime incarceration rate approaching half of all Black trans women¹³.

Inside, the combination of housing placement (trans women are still often housed in men's facilities), inadequate access to gender-affirming care, and elevated risk of sexual violence stacks harm on top of harm — including HIV acquisition risk¹³. Continuity of both hormone therapy and ART on release is often broken at the same time.

Florida

Florida has one of the largest prison populations in the country and one of the highest HIV rates. The Florida Department of Corrections (FDC) operates a system that includes thousands of people living with HIV at any given time.

Florida's HIV criminalization laws create a specific added burden for incarcerated people living with HIV: a person can face enhanced criminal charges related to HIV regardless of viral suppression, adding legal complexity to an already difficult situation¹⁴. Incarcerated Floridians living with HIV navigate both their care and potential legal consequences at the same time. (For the state law itself, see our Florida HIV criminalization deep dive.)

Re-entry in Florida is particularly challenging given the state's decision not to expand Medicaid (meaning many formerly incarcerated people face longer insurance gaps), its lack of a Section 1115 reentry waiver (see above), the complexity of ADAP enrollment, and housing instability rates among released individuals.

AIDS service organizations in Florida's major cities — Miami, Tampa, Orlando, Jacksonville, Fort Lauderdale — often have specific re-entry programming or can connect formerly incarcerated people living with HIV with services. Use our care locator to find help.

Rights and advocacy

Legal rights of incarcerated people living with HIV

Incarcerated people have a constitutional right to adequate medical care under the Estelle v. Gamble deliberate-indifference standard⁶. In practice, this means that correctional facilities must provide HIV treatment — but the floor is "adequate," not optimal, and enforcement requires litigation. Organizations including the ACLU National Prison Project, Lambda Legal, and the Center for HIV Law and Policy have litigated HIV care cases in correctional settings.

Confidentiality

HIV status is supposed to be confidential inside correctional facilities — but breaches happen, and the consequences inside (stigma, discrimination, occasionally violence) can be severe. Incarcerated people living with HIV have the right to medical privacy, though this right can be difficult to enforce in a closed institutional environment.

Advocacy organizations

Organizations working at the HIV-incarceration intersection include the Center for HIV Law and Policy, the ACLU's National Prison Project, the Positive Women's Network, and local AIDS service organizations with re-entry programs. HIV advocacy that doesn't include correctional settings is incomplete advocacy.